Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response

¹Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, New York.
²Department of Thoracic Surgery, Weill Cornell Medical College, New York, New York.
³Department of Surgery, Weill Cornell Medical College, New York, New York.
⁴Department of Pathology, Weill Cornell Medical College, New York, New York.
⁵Division of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York.
⁶Clinical Trials Office, Weill Cornell Medical College, New York, New York.
⁷Memorial Sloan-Kettering Cancer Center, New York, New York.
⁸Division of Regenerative Medicine, Department of Internal Medicine; Weill Cornell Medical College, New York, New York.

↵*Corresponding Author:
Bryan J. Schneider, C411 Med Inn Building, 1500 East Medical Center Drive, SPC 5848, Ann Arbor, MI 48019. Phone: 734-647-8921; Fax: 734-647-8792; E-mail: bryansch{at}med.umich.edu